Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2018

Open Access 01-12-2018 | Research article

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America

Authors: Iván Cherrez-Ojeda, Vincent Cottin, Juan Carlos Calderón, César Delgado, Erick Calero, Daniel Simanca-Racines, Silvia Quadrelli, Annia Cherrez

Published in: BMC Pulmonary Medicine | Issue 1/2018

Login to get access

Abstract

Background

The aim of our study was to assess current practice patterns and attitudes towards diagnosis and management of idiopathic pulmonary fibrosis (IPF) patients in Latin America.

Methods

A Cross-sectional survey was developed and up to 455 physicians were enrolled. We used a rigorous method of validation using the translated version of the AIR Survey.

Results

Mean age was 47.5 years (SD 12.6) with 20.4 years (SD 12.3) of practice. In around 30% of physicians were reported access to radiologist, pathologist and multidisciplinary team. Despite almost all physicians reported that (ATS/ERS/JRS/ALAT) guidelines are useful, half of them prescribed corticoids for treatment of disease. Most respondents (69.9%) reported cough as the presenting symptom. Around 80% considered IPF to be an important clinical disorder, and felt that identifying patients at risk for IPF was important or extremely important. However, only 59.7% felt confident in managing patients with IPF, and similar numbers (60.8%) felt confident about their knowledge. Pulmonologist have more confidence and management of IPF that no pulmonologist.

Conclusion

The results of this survey of Latin American physicians could help to fill gaps regarding awareness, management and treatment of IPF and improve earlier diagnosis of IPF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral
3.
go back to reference Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:58–64.CrossRefPubMed Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:58–64.CrossRefPubMed
4.
go back to reference Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355–61.CrossRefPubMed Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355–61.CrossRefPubMed
5.
go back to reference Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRefPubMed Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.CrossRefPubMed
6.
go back to reference Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.CrossRefPubMed Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.CrossRefPubMed
7.
go back to reference Flaherty KR, King TE, Jr., Raghu G, Lynch JP, 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004, 170:904–910. Flaherty KR, King TE, Jr., Raghu G, Lynch JP, 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004, 170:904–910.
8.
go back to reference Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev. 2014;23:225–30.CrossRefPubMed Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev. 2014;23:225–30.CrossRefPubMed
9.
go back to reference Cottin V, Cadranel J, Crestani B, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Valeyre D, Wallaert B, et al. Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med. 2014;108:195–202.CrossRefPubMed Cottin V, Cadranel J, Crestani B, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Valeyre D, Wallaert B, et al. Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. Respir Med. 2014;108:195–202.CrossRefPubMed
10.
go back to reference Cottin V, Bergot E, Bourdin A, Cadranel J, Camus P, Crestani B, Dalphin JC, Delaval P, Dromer C, Israel-Biet D, et al. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Res. 2015;1 Cottin V, Bergot E, Bourdin A, Cadranel J, Camus P, Crestani B, Dalphin JC, Delaval P, Dromer C, Israel-Biet D, et al. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Res. 2015;1
11.
go back to reference Troy LK, Chapman SA, Lake F, Wilsher ML, Honeysett LB, Macansh S, Corte TJ. Current Australasian practice for diagnosis and management of idiopathic pulmonary fibrosis: where are we now? Respirology. 2015;20:647–53.CrossRefPubMed Troy LK, Chapman SA, Lake F, Wilsher ML, Honeysett LB, Macansh S, Corte TJ. Current Australasian practice for diagnosis and management of idiopathic pulmonary fibrosis: where are we now? Respirology. 2015;20:647–53.CrossRefPubMed
12.
go back to reference Sharp C, Maher TM, Welham S, Gibbons M: UK trainee experience in interstitial lung disease: results from a British Thoracic Society survey. Thorax 2014:thoraxjnl-2014-206397. Sharp C, Maher TM, Welham S, Gibbons M: UK trainee experience in interstitial lung disease: results from a British Thoracic Society survey. Thorax 2014:thoraxjnl-2014-206397.
13.
go back to reference Sperber AD. Translation and validation of study instruments for cross-cultural research. Gastroenterology. 2004;126:S124–8.CrossRefPubMed Sperber AD. Translation and validation of study instruments for cross-cultural research. Gastroenterology. 2004;126:S124–8.CrossRefPubMed
14.
go back to reference Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.CrossRefPubMed Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.CrossRefPubMed
15.
go back to reference Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.CrossRefPubMed Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.CrossRefPubMed
16.
go back to reference Xaubet A, Ancochea J, Bollo E, Fernandez-Fabrellas E, Franquet T, Molina-Molina M, Montero MA, Serrano-Mollar A, Sociedad Espanola de Neumologia y Cirugia Toracica research group on diffuse pulmonary D: Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) research group on diffuse pulmonary diseases. Arch Bronconeumol 2013, 49:343–353. Xaubet A, Ancochea J, Bollo E, Fernandez-Fabrellas E, Franquet T, Molina-Molina M, Montero MA, Serrano-Mollar A, Sociedad Espanola de Neumologia y Cirugia Toracica research group on diffuse pulmonary D: Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) research group on diffuse pulmonary diseases. Arch Bronconeumol 2013, 49:343–353.
17.
go back to reference Selman M, Undarraga A: Recomendaciones para el diagnóstico y tratamiento de la Fibrosis Pulmonar Idiopática. RESPIRAR 2015:e24. Selman M, Undarraga A: Recomendaciones para el diagnóstico y tratamiento de la Fibrosis Pulmonar Idiopática. RESPIRAR 2015:e24.
Metadata
Title
Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Authors
Iván Cherrez-Ojeda
Vincent Cottin
Juan Carlos Calderón
César Delgado
Erick Calero
Daniel Simanca-Racines
Silvia Quadrelli
Annia Cherrez
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2018
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-017-0569-1

Other articles of this Issue 1/2018

BMC Pulmonary Medicine 1/2018 Go to the issue